ONCY Financials

Income Statement
MetricQ2 2026Q1 2026Q2 2025Q1 2025Q1 2016
Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
9.4M
+1.1%
9.3M
+99.5%
4.7M
-7.4%
5.0M
+22.9%
4.1M
R&D
4.3M
-6.4%
4.6M
+137.6%
1.9M
-31.6%
2.8M
+2.7%
2.7M
SG&A
5.1M
+8.2%
4.7M
+72.9%
2.7M
+23.1%
2.2M
Operating Income
-9379000
-1.1%
-9281000
-99.5%
-4651000
+7.4%
-5021000
-22.9%
-4086541
EBITDA
-9364000
-1.1%
-9265000
-100.0%
-4633000
+7.4%
-5002000
-23.8%
-4040599
Net Income
-9442000
-2.2%
-9243000
-75.2%
-5277000
-12.0%
-4711000
-17.3%
-4016775
EPS (Basic)
$-0.08
+0.0%
$-0.08
-33.3%
$-0.06
+0.0%
$-0.06
+79.3%
$-0.29
EPS (Diluted)
$-0.08
+0.0%
$-0.08
-33.3%
$-0.06
+0.0%
$-0.06
+79.3%
$-0.29
Shares (Diluted)
119.7M
+6.6%
112.3M
+23.4%
91.0M
+7.5%
84.6M
+580.2%
12.4M
Oncolytics Biotech, Inc. Common Shares (ONCY) — Financials